title: Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis.
abstract: Due to the emergence of Staphylococcus aureus with reduced vancomycin susceptibility, newer antibiotics, including daptomycin, have been used to treat methicillin-resistant S aureus infections. Daptomycin is a cyclic lipopeptide that is approved to treat S aureus bacteremia and right-sided endocarditis, and reports of S aureus with reduced susceptibility to daptomycin are infrequent. To our knowledge, the present report describes the first Canadian case of daptomycin-nonsusceptible, vancomycin-intermediate S aureus infection.
authors.affiliation: Michael G DeGroote School of Medicine, McMaster University;
authors.forename: Ryan
authors.initials: R
authors.lastname: Yu
authors.forename: Suzanne E
authors.initials: SE
authors.lastname: Dale
authors.forename: Deborah
authors.initials: D
authors.lastname: Yamamura
authors.forename: Vida
authors.initials: V
authors.lastname: Stankus
authors.forename: Christine
authors.initials: C
authors.lastname: Lee
keywords: Daptomycin nonsusceptible; Endocarditis; Methicillin-resistant Staphylococcus aureus; Vancomycin intermediate resistance